Oncopeptides AB - Company Review
Oncopeptides AB - Company ReviewSummary
Oncopeptides AB (Oncopeptides) is a pharmaceutical company which focuses on the development of oncology therapies to treat multiple myeloma. Its lead product Ygalo (melflufen), a peptidase potentiated therapy and a potent anti-angiogenetic compound. Ygalo is intended for the treatment of patients with late-stage relapsed and refractory multiple myeloma. Oncopeptides initiated an additional Phase II clinical trial of Ygalo in combination with dexamethasone. The company conducts Ygalo’s clinical study in collaboration with six institutions across the US and Europe including Dana-Farber Cancer Institute. Oncopeptides is headquartered in Stockholm, Sweden.
This comprehensive company report of Oncopeptides AB provides you with company's businesses and operations information.
The profile contains critical company information including,
- Company Overview - A detailed description of the company's operations and business divisions.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
GlobalData is a one-stop solution for actionable insight into the pharmaceutical and medical device sectors. Together with the best team of researchers, analysts, epidemiologists and consultants, and an unmatched suite of proprietary databases, we provide high-quality, accurate and transparent insight that can help you achieve growth and increase business value.
Our valuable research and consulting solutions ensure you stay at the forefront of the industry by integrating accurate market forecasts and healthcare analytics on the latest trends and developments. Among other benefits, our informed healthcare industry perspectives have assisted businesses based across the pharmaceuticals, biotechnology and medical equipment markets in making strategic decisions that have increased the value of their products and services.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.